Profound Medical Financials - Benzinga

Profound Medical Corp

PROFNASDAQ

Trade with Public

Trade with Public

$6.87

0.0210.31%

Last update: Aug 31, 2:28 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Profound Medical Financials

Profound Medical (PROF) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Profound Medical Affirms FY2026 Sales Guidance of $25.000M vs $26.858M Est

Profound Medical (NASDAQ:PROF) affirms FY2026 sales outlook from $25.000 million to $25.000 million vs $26.858 million estimate.

Benzinga Newsdesk

PRO
Profound Medical Q2 EPS $(0.26), Inline, Sales $2.483M Miss $5.500M Estimate

Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.52) per share from the same period last year. The

Benzinga Newsdesk

PRO
Profound Medical Sees FY2026 Sales $25.000M

Profound Medical (CSE2: PRN) sees FY2026 sales of $25.000 million.

Benzinga Newsdesk

PRO
Profound Medical Q1 EPS $(0.19) Beats $(0.35) Estimate, Sales $5.337M Miss $6.648M Estimate

Profound Medical (TSX:PRN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.35) by 45.71 percent. This is a 47.22 percent increase over losses of $(0.36) per share from the

Benzinga Newsdesk

Profound Medical Q4 Earnings Assessment

Benzinga Insights

Earnings Summary: Profound Medical Q4

Benzinga Insights